These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26116295)

  • 1. Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
    Geynisman DM; Ross EA; Plimack ER
    Eur Urol; 2015 Oct; 68(4):578-80. PubMed ID: 26116295
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of disease matters when it comes to systemic therapy for prostate cancer.
    Harrison MR; Armstrong AJ
    Eur Urol; 2015 Mar; 67(3):448-50. PubMed ID: 24612662
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
    Lu K
    Eur Urol; 2015 Sep; 68(3):e55-6. PubMed ID: 25865060
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
    Azad AA; Chi KN
    Eur Urol; 2015 Sep; 68(3):e57-8. PubMed ID: 25864159
    [No Abstract]   [Full Text] [Related]  

  • 6. STAMPEDE-ing towards androgen biosynthesis inhibition for treatment of high-risk hormone-naïve prostate cancer: changing the LATITUDE.
    Klaassen Z; Murphy DG
    BJU Int; 2018 Jan; 121(1):9-11. PubMed ID: 28990349
    [No Abstract]   [Full Text] [Related]  

  • 7. Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?
    Suzman D; Eisenberger M
    Eur Urol; 2014 Nov; 66(5):826-8. PubMed ID: 24751214
    [No Abstract]   [Full Text] [Related]  

  • 8. Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.
    Kunath F; Goebell PJ; Wullich B; Sikic D; Kahlmeyer A
    World J Urol; 2020 Mar; 38(3):601-611. PubMed ID: 30830274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons.
    Hamid AA; Morris MJ; Davis ID
    Eur Urol Focus; 2019 Mar; 5(2):165-167. PubMed ID: 30559064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
    Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D
    Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
    Petrioli R; Francini E; Laera L; Fiaschi AI; Ponchietti R; Roviello G
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):439-45. PubMed ID: 26082421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?
    Aoun F; El Rassy E; Sleilaty G; Assi T; Bakouny Z; Kattan J
    Future Oncol; 2017 Dec; 13(30):2785-2790. PubMed ID: 29188727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone.
    Jones RJ
    Oncology (Williston Park); 2018 May; 32(5):223, 226-7, 247. PubMed ID: 29847852
    [No Abstract]   [Full Text] [Related]  

  • 14. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Chemotherapy.
    Isaacsson Velho P; Eisenberger MA
    Oncology (Williston Park); 2018 May; 32(5):223-6. PubMed ID: 29847851
    [No Abstract]   [Full Text] [Related]  

  • 17. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
    Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
    BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients.
    Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; Vermeulen A; Poggesi I; Nandy P
    Clin Cancer Res; 2015 Jul; 21(14):3170-7. PubMed ID: 25829400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid oral desensitization protocol to abiraterone acetate.
    Verdu M; Torres-Degayon V; Hassan-Bennis M
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):668-669. PubMed ID: 29432966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.